Symposium

[GS01] Young pharmaceutical scientists accelerate translational research in infectious disease

Sat. Mar 27, 2021 9:30 AM - 11:30 AM [Room E] Oral Presentation E (Online)

Organizer: Sho Tashiro (Keio Univ., Fac. Pharm., Grad. Sch. Pharm. Sci.), Chika Ogami (Pharm. Univ. Toyama)

Antimicrobial-resistant bacteria are the cause of death in an estimated 700,000 people annually worldwide, and this number is predicted to increase to 10 million by 2050 if efforts are not made to reduce resistance or develop new antibiotics. Therefore, research, development, and proper use of antibiotics are urgent issues. However, development is decreasing, and misuse and abuse remain common, which lead to their spread.
In this symposium, 6 young pharmaceutical scientists will present from varying backgrounds of infectious research (pre-clinical studies [PCS] ~ clinical studies [CS]). Young scientists who are actively trying to overcome the threat and improve clinical antibacterial chemotherapy will share novel medical seeds found in daily research and their opinions. These seeds are expected to advance both PCS and CS, which will aid in the development of new therapies.
After this symposium, young scientists who are performing PCS and CS are anticipated to collaborate organically with each other to develop innovative next-generation treatments. We consider this symposium to be a shortcut to overcoming antimicrobial-resistant bacteria.

+Add all to schedule

オーガナイザー挨拶：田代渉（慶應大薬） (9:30 AM - 9:35 AM)

9:35 AM - 9:53 AM

[GS01-1] Antimicrobial resistance of Pseudomonas. aeruginosa.: Differences of resistant mechanisms between clinical isolates and laboratory isolates.

○Itsuki Wakisaka¹, Masaya Endou¹, Daichi Morita^1,2, Shizuo Kayama^3,4,5, Atsushi Ota⁶, Takanori Kumagai^1,2, Humito Maruyama⁶, Motoyuki Sugai^3,4,5, Teruo Kuroda^1,2 (1. Sch. Phar., Hiroshima Univ, 2. Dept. Microbiol., Grad. Sch. Biomed. Heal. Sci., Hiroshima Univ., 3. Anti. Resis. Res. Cent., Nat. Inst. Infect. Dis., 4. Proj. Res. Cent. Noso. Infect. Dis., Hiroshima Univ., 5. Dept. Anti. Res., Grad. Sch. Biomed. Heal. Sci., Hiroshima Univ., 6. Dept. Microb. Gen. Ecol. Lab., Office Acad. Res. Indust. Gov. Commun. Collaboration, Hiroshima Univ.)

9:53 AM - 10:11 AM

[GS01-2] Efficacy of in vitro rifampicin combination therapy against biofilm-producing S. aureus

○Takashi Uno^1,2, Takumi Sato¹, Ryota Ito¹, Masato Kawamura¹, Shigeru Fujimura¹ (1. Tohoku Med. Pharm. Univ., 2. Tohoku Med. Pharm. Univ. Hosp.)

10:11 AM - 10:30 AM

[GS01-3] PK/PD evaluation of existing antimicrobials against ESBL-producing E. coli in in vitro and in vivo a murine thigh infection model

○Sho Tashiro¹, Kazuaki Matsumoto¹ (1. Keio Univ., Fac. Pharm., Grad. Sch. Pharm. Sci.)

10:30 AM - 10:48 AM

[GS01-4] Pharmacometrics modelling to predict pharmacokinetics and clinical efficacy of teicoplanin

○Chika Ogami¹, Yasuhiro Tsuji², Yuichi Muraki³, Masahiro Okuda⁴, Hideto To¹ (1. Pharm. Univ. Toyama, 2. Pharm. Nihon Univ., 3. Pharm. Kyoto-yakka Univ., 4. Pharm. Hosp. Osaka)

10:48 AM - 11:06 AM

[GS01-5] Individualized dosing regimens of ampicillin-sulbactam based on physiologically-based pharmacokinetics/pharmacodynamics model analysis

○Tetsushu Onita^1,2 (1. Dept. Clin. Pharmacother, Hiroshima Univ., 2. Dept. Pharm, Shimane Univ. Hosp.)

11:06 AM - 11:25 AM

[GS01-6] Construction of a simple flowchart to predict the risk of vancomycin induced acute kidney injury ~utilizing data mining methods in infectious disease therapy~

○Takayuki Miyai¹, Shungo Imai², Mitsuru Sugawara^2,3 (1. Grad. Sch. Life Sci., Hokkaido Univ., 2. Grad. Sch. Pharm. Sci., Hokkaido Univ., 3. Dept. Pharm., Hokkaido Univ. Hosp.)

総括：田代渉（慶應大薬）、尾上知佳（富山大院薬） (11:25 AM - 11:30 AM)

Session information